GEXVal Inc. is an R&D-focused drug discovery company founded in 2018 with a mission to develop pioneering solutions for rare and incurable diseases. The company's dedication to providing innovative and cost-effective treatment options in the Health Care industry sets it apart. GEXVal's recent ¥450.00M Series C investment on 04 December 2023 saw participation from notable investors including Mitsubishi UFJ Capital, SMBC Venture Capital, Axil Capital, UTC 2019 BioVentureFund, and Oita Venture Capital. This latest investment underscores confidence in GEXVal's commitment to improving lives through groundbreaking treatments, further solidifying its position as an innovative leader in the field.
No recent news or press coverage available for GEXVal Inc..